巴曲酶联合前列地尔治疗极重度突发性聋的临床疗效观察

目的：观察巴曲酶注射液联合前列地尔注射液治疗极重度突发性聋的有效性和安全性。方法：将56例符合纳入标准的患者随机分为2组，在基础治疗相同情况下，治疗组使用巴曲酶注射液联合前列地尔、对照组单独使用前列地尔，疗程10 d，观察2组患者听力及伴随症状的改善情况。结果：治疗组对极重度突发性聋听力改善的总有效率为70.0%，对照组为46.1%，2组间比较，差异有极显著性统计学意义（P<0.01），对伴随症状改善治疗组优于对照组。同时临床观察期间的2组均未发现明显的不良反应。结论：巴曲酶注射液联合前列地尔治疗极重度突发性聋是具有良好的疗效且安全性好，值得临床推广。

Clinical efficacy of batroxobin combined with alprostadil in the treatment of severe sudden deafness

OBJECTIVE To observe the efficacy and safety of batroxobin injection combined with alprostadil injection in the treatment of severe sudden deafness.METHODS Totally 56 cases of patients met the inclusion criteria were divided into two groups.Based on the same basic therapy,patients in the treatment group received batroxobin injection combined with alprostadil,patients in control group received alprostadil alone.The treatment lasted for 10 days.Hearing and hearing improvement were observed in two groups.RESULTS The total effective rate was 70.0% in treatment group and 46.1% in control group.There was no significant difference between the two groups (P<0.01).The treatment group showed superior improving effects on the accompanying symptoms to control group.No obvious adverse reaction was observed during the study.CONCLUSION Batroxobin injection combined with alprostadil is effective and safe in the treatment of severe sudden sensorineural hearing loss,and is worthy of clinical promotion.